CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 69 enrolled
Drug / intervention
Bevacizumab +2 moredrug
Likely dose
Bevacizumab 0.16 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01854593
NCT01854593Phase 4Completed

Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy

Nihon University·interventional·Posted May 15, 2013·Updated Jul 14, 2014

In Brief

A Phase 4 clinical trial evaluating Bevacizumab, Vitrectomy, and 1 other intervention for Proliferative Diabetic Retinopathy and 2 related conditions. Completed, enrolled 69 participants across 1 site.

Detailed Summary

We hypothesized that to reduce the adverse effects of intravitreal bevacizumab on ocular tissue and whole body, intravitreal injection of a low concentration of bevacizumab and conducting vitrectomy shortly after the injection is useful. In the present prospective, double-masked, randomized, controlled study, we aimed to verify the usefulness of intravitreal injection of 0.16 mg/0.05 ml bevacizumab one day before conducting vitrectomy for PDR.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 15, 2013
Enrollment StartMay 1, 2012
Primary CompletionAug 1, 2013
Study CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.1 years ago

Interventions

Bevacizumabdrug

0.16 mg/0.05 ml bevacizumab (single injection on 1 day before operation)

Vitrectomyprocedure

vitrectomy of 25 gauge system.

Sham injectiondevice

Sham injection one day before vitrectomy